News

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee the corporate business and commercial center. As part of the executive leadership team, Ballish will focus on growing the company’s global footprint and reinforcing ATCC’s position as the de facto leader in biological resources.

“We are fortunate to add Greg’s considerable experience and inclusive management style to our executive team, and we look forward to seeing the impact of his commercial leadership,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “In his role, Greg will ensure that we remain a customer-centric organization and continue our commitment to exceeding expectations and fostering long-lasting partnerships with the institutions and organizations we serve.”

Ballish brings an extensive sales, marketing and operations background in the diagnostics, pharmaceuticals, medical devices, transfusion medicine and medical distribution markets to ATCC. He has guided organizations to top market share positions and held key leadership sales and marketing roles for companies including Abbott Labs, DuPont, Johnson & Johnson, LabCorp, LGC Clinical Diagnostics, Meridian Bioscience, Terumo BCT and the American Red Cross. Ballish holds a Master of Business Administration from Arizona State University and a Bachelor of Science in finance from Miami University.

Recent News

08/10/2026

Expanding visibility with wearable blood pressure monitoring: CareTaker

In higher-risk patient populations, across all points of care, a patient’s condition can deteriorate quickly between routine vital sign checks, creating critical gaps in visibility and leaving clinical deterioration undetected between rounds. Continuous clinical-grade non-invasive blood pressure (CNIBP) monitoring, combined with hemodynamic trending, helps close these gaps by providing a more complete view of patient

08/10/2026

BIO-CAT Joins the Lallemand Family

BIO-CAT is pleased to join the Lallemand family as we begin an exciting new chapter together. Effective July 31, 2026, Lallemand Inc. has completed its acquisition of BIO-CAT Enzymes & Microbials. Together, we are combining complementary expertise in enzymes, microbial technologies, fermentation, and life science innovation to create an even stronger platform for developing next-generation

08/05/2026

Virginia Catalyst Announces Opening of Grant Round 20

The Virginia Catalyst announced that it is accepting letters of intent (LOI) for Grant Round 20 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy. “The Virginia Catalyst is excited to open Grant Round 20 to continue our support of Virginia’s